Results 221 to 230 of about 497,995 (362)

Rethinking Strategies for a Pharmaceutical Approach to Pain Related to Connective Tissue–Related Raynaud Phenomenon in the United States

open access: yesArthritis Care &Research, EarlyView.
Objective There are no US Food and Drug Administration–approved therapies for Raynaud phenomenon (RP) in the United States. Clinical trials have been challenged by study design. Important advances in RP patient‐reported outcome measures and mechanistic quantification allow RP‐related pain characterization.
Tracy M. Frech   +4 more
wiley   +1 more source

Accuracy of diagnostic codes and algorithms used to identify rheumatoid arthritis and juvenile idiopathic arthritis in administrative claims and electronic health records: systematic review and meta‐analysis.

open access: yesArthritis Care &Research, Accepted Article.
Objective This systematic review aimed to assess the diagnostic accuracy of algorithms used to identify rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA) in electronic health records (EHRs). Methods We searched MEDLINE, Embase, and CENTRAL databases and included studies that validated case definitions against a reference standard such ...
Constanza Saka‐Herrán   +10 more
wiley   +1 more source

Rural Food Forward: An Appetite for Change. [PDF]

open access: yesAust J Rural Health
McNaught K, Sjepcevich G.
europepmc   +1 more source

Leptin Receptor−Deficient Obese Zucker Rats Reduce Their Food Intake in Response to a Systemic Supply of Calories From Glucose [PDF]

open access: bronze, 2003
Marc Gilbert   +4 more
openalex   +1 more source

Sarilumab in Polyarticular‐Course Juvenile Idiopathic Arthritis: Dose‐Finding and One‐Year Analysis of a Phase 2b, Open‐Label, Multicenter Study

open access: yesArthritis Care &Research, Accepted Article.
Objective This study assessed sarilumab in treating patients with polyarticular‐course juvenile idiopathic arthritis (pcJIA). Methods This phase 2b, open‐label study (NCT02776735) consisted of three sequential parts (each with a core‐treatment and extension‐phase). During part 1, three doses were assessed in two weight groups (Group A/B: ≥30–60 kg/≥10–<
Fabrizio De Benedetti   +19 more
wiley   +1 more source

Home - About - Disclaimer - Privacy